...
首页> 外文期刊>Vaccine >Immunoadjuvant capacity of flagellin and mannosamine-coated poly(anhydride) nanoparticles in oral vaccination.
【24h】

Immunoadjuvant capacity of flagellin and mannosamine-coated poly(anhydride) nanoparticles in oral vaccination.

机译:鞭毛蛋白和甘露糖胺涂层的聚(酸酐)纳米颗粒在口服疫苗中的免疫佐剂能力。

获取原文
获取原文并翻译 | 示例

摘要

Bioadhesive poly(anhydride) nanoparticles coated with mannose (M-NP) or Salmonella Enteritidis derived flagellin (F-NP) were designed to be applied in oral vaccination strategies using ovalbumin (OVA) as antigen model. Nanoparticles formulations (OVA-M-NP, OVA-F-NP and control OVA-NP) were characterized and evaluated in BALB/c mice. OVA-M-NP and OVA-F-NP displayed a size of about 300-400 nm and were efficiently coated with the respective ligand, Systemic and mucosal immune responses reported after S.C. and oral administration, indicated that a single dose of OVA-M-NP and OVA-F-NP, elicited higher and balanced systemic specific antibody responses [IgG1 (Th2-response) and IgG2a (Th1-response)] compared to non-coated ones. In addition, oral immunization using OVA-M-NP or OVAF-NP was able to elicit a higher levels of intestinal secretory IgA compared to S.C. In summary, oral immunization by bioadhesive mannosylated or flagellin nanoparticles demonstrated strong long lasting systemic and mucosal immune responses than the respective non-conjugated vectors.
机译:设计使用甘露糖(M-NP)或肠炎沙门氏菌衍生的鞭毛蛋白(F-NP)包覆的生物粘附性聚(酸酐)纳米颗粒,以卵清蛋白(OVA)作为抗原模型,用于口服疫苗接种策略。在BALB / c小鼠中表征和评估了纳米颗粒制剂(OVA-M-NP,OVA-F-NP和对照OVA-NP)。 OVA-M-NP和OVA-F-NP的大小约为300-400 nm,并有效地被各自的配体包被。SC和口服给药后报告的全身和粘膜免疫反应表明,单剂OVA-M -NP和OVA-F-NP与未包被的相比,引起更高且平衡的全身特异性抗体反应[IgG1(Th2反应)和IgG2a(Th1反应)]。此外,与SC相比,使用OVA-M-NP或OVAF-NP进行的口服免疫能够引发更高水平的肠道分泌IgA。总之,与甘露糖基化或鞭毛蛋白生物粘附相关的口服免疫证明,与全身和黏膜免疫反应相比,持久性强各自的非共轭载体。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号